Indication
Hematological Malignancy
18 clinical trials
26 products
4 drugs
Product
Isavuconazonium sulfateClinical trial
A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric PatientsStatus: Completed, Estimated PCD: 2019-07-05
Clinical trial
A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.Status: Recruiting, Estimated PCD: 2024-12-30
Product
SG2501Clinical trial
A Phase 1 Study of SG301 in Subjects With Hematological MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
SG301Product
PelabresibClinical trial
A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2023-03-08
Product
YY201Clinical trial
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2026-12-30
Product
ATG-017Clinical trial
A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2024-02-29
Product
ATG-017+NivolumabProduct
IsavuconazoniumClinical trial
A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological MalignanciesStatus: Completed, Estimated PCD: 2018-12-21
Product
DexamethasoneProduct
IsatuximabProduct
OT-A201Clinical trial
A First-in-human, Dose-escalation Followed by Expansion Study to Assess the Safety and Preliminary Efficacy of a Bispecific Antibody OT-A201 as Monotherapy and in Combination Therapy in Patients With Selected Hematological Malignancies and Solid TumorsStatus: Recruiting, Estimated PCD: 2027-01-01
Product
BevacizumabProduct
IMidsProduct
PaclitaxelProduct
TBD CompoundClinical trial
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological TumoursStatus: Recruiting, Estimated PCD: 2025-11-15
Product
CAR-T cell therapyClinical trial
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationStatus: Recruiting, Estimated PCD: 2025-11-16
Drug
MelphalanProduct
FludarabineClinical trial
Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2024-05-31
Product
EtoposideProduct
CytarabineDrug
PEG-rhG-CSFClinical trial
REINFORCED PROPHYLAXIS OF GVH IN ELDERLY PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: USE OF A LOW DOSE OF POST-ALLOGRAFT ANTI-LYMPHOCYTIC SERUMStatus: Not yet recruiting, Estimated PCD: 2026-03-31
Product
ThymoglobulinClinical trial
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Following Fludarbine/Melphalan/Total Body Irradiation Conditioning RegimenStatus: Recruiting, Estimated PCD: 2025-01-01
Product
BortezomibClinical trial
A Multi-center, Prospective Study of Clinical Outcome and Immune Reconstruction in G-CSF/ATG and PT-Cy Based Haploidentical TransplantationStatus: Recruiting, Estimated PCD: 2025-07-01
Product
ATGClinical trial
Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged NeutropeniaStatus: Recruiting, Estimated PCD: 2028-02-01
Product
EravacyclineClinical trial
Is Ibrutinib-related Atrial Fibrillation Dose Dependent: Insights From the WHO Pharmacovigilance DatabaseStatus: Not yet recruiting, Estimated PCD: 2024-05-01
Product
IbrutinibClinical trial
A Phase I Trial of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)Status: Completed, Estimated PCD: 2016-03-01
Clinical trial
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological MalignancesStatus: Recruiting, Estimated PCD: 2026-12-30
Drug
fludarabineDrug
cyclophosphamide